Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase I/Ib Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction GEJ Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumor Have Claudin CLDN 18.2 Expression
Study Type: Treatment
Phase: I
NCTID: NCT05365581
Principal Investigator:
Anup Kasi
NRG-GI011: A PHASE III RANDOMIZED TRIAL OF DOSE ESCALATED RADIATION IN LOCALLY ADVANCED PANCREAS CANCER LAPC PATIENTS LAP100
Study Type: Treatment
Phase: III
NCTID: NCT06958328
Principal Investigator:
Ryan Morse
Pancreatic Cancer Early Detection PRECEDE Consortium
Study Type: Other
Phase: N/A
NCTID: NCT04970056
Principal Investigator:
Ajay Bansal
A Phase 1/2 Study of M3814 Peposertib in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
Study Type: Treatment
Phase: I/II
NCTID: NCT04172532
Principal Investigator:
Anup Kasi
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma PDAC
Study Type: Treatment
Phase: III
NCTID: NCT07252232
Principal Investigator:
Anup Kasi
Study of RMC-9805 with or without RMC-6236 in Combination with Cetuximab-based Therapies in Patients with RAS G12D-Mutant Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma ? Subprotocol E
Study Type: Treatment
Phase: I/II
NCTID: NCT06445062
Principal Investigator:
Raed Al-Rajabi
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Study Type: Treatment
Phase: II
NCTID: NCT04858334
Principal Investigator:
Anup Kasi